NCT07753460 Low-Level Laser Therapy in the Treatment of Trigger Finger
| NCT ID | NCT07753460 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dokuz Eylul University |
| Condition | Trigger Finger |
| Study Type | INTERVENTIONAL |
| Enrollment | 91 participants |
| Start Date | 2025-08-07 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 91 participants in total. It began in 2025-08-07 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Trigger finger, also known as stenosing tenosynovitis, is one of the most common disorders affecting the hand. Its lifetime prevalence is 2-3%. Patients typically present with locking of the affected finger during flexion and painful catching during extension. In mild cases, pain, swelling, and morning stiffness may be present without triggering. In more severe cases, the affected finger may become locked in flexion. Conservative treatment methods, corticosteroid injections, and surgical interventions can be used in the treatment of trigger finger. Conservative treatment options include activity modification, splint immobilization, exercise programs, massage, physical therapy modalities including extracorporeal shock wave therapy and therapeutic ultrasound, and nonsteroidal anti-inflammatory drugs (NSAIDs). Splinting is an inexpensive and effective treatment option for trigger finger. Low-level laser therapy (LLLT) is a treatment modality based on photobiomodulation, which leads to biological changes in living organisms through the interaction of photons with atoms or molecules. LLLT is used to promote wound healing and tissue repair, prevent tissue damage, reduce inflammation and edema, and provide analgesia. Several studies have demonstrated the effectiveness of LLLT in the treatment of various musculoskeletal disorders. This study aims to investigate the effects of adding active LLLT to splint treatment in patients with trigger finger. Patients receiving active LLLT plus splint treatment will be compared with those receiving sham LLLT plus splint treatment in terms of clinical and ultrasonographic outcomes.
Eligibility Criteria
Inclusion Criteria: * Applying to the outpatient clinic of the Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Dokuz Eylül University * A clinical diagnosis of trigger finger based on typical pain and tenderness over the A1 pulley accompanied by triggering of the affected finger * Willingness to participate in the study Exclusion Criteria: * Multiple trigger fingers in the same hand * Fixed deformity (Quinnell grade 4) * Splint treatment, physical therapy, or steroid injection for the affected trigger finger within the previous 6 months * Previous surgery for the affected trigger finger * Musculoskeletal disorders or peripheral nerve injury involving the ipsilateral upper extremity * Rheumatoid arthritis, carpal tunnel syndrome, Dupuytren disease, amyloidosis, or mucopolysaccharidosis * Active infection, bleeding, skin lesions, or an implant at the treatment site * Radiotherapy within the previous 6 months * Photodermatosis, photosensitivity, or systemic lupus erythematosus * Pregnancy, epilepsy, coagulopathy, active malignancy, or the presence of a cardiac pacemaker * Cognitive impairment that precludes understanding of the study questionnaires.
Contact & Investigator
Elif Akalın, Prof, MD
STUDY CHAIR
Dokuz Eylul University
Frequently Asked Questions
Who can join the NCT07753460 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Trigger Finger. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07753460 currently recruiting?
Yes, NCT07753460 is actively recruiting participants. Contact the research team at gozde.kirimkaya@deu.edu.tr for enrollment information.
Where is the NCT07753460 trial being conducted?
This trial is being conducted at Izmir, Turkey (Türkiye).
Who is sponsoring the NCT07753460 clinical trial?
NCT07753460 is sponsored by Dokuz Eylul University. The principal investigator is Elif Akalın, Prof, MD at Dokuz Eylul University. The trial plans to enroll 91 participants.